JAK2V617F: more than a clonal marker?
Tefferi
Ayalew
A
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. tefferi.ayalew@mayo.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics* / Q000378:metabolism*; D009154:Mutation / Q000235:genetics; D011379:Prognosis; D013920:Thrombocythemia, Essential / Q000188:drug therapy / Q000201:enzymology / Q000453:epidemiology / Q000235:genetics; D014633:Valine / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D053614:Janus Kinase 2; D014633:Valine